Abstract Library

#3062 The Splicing Factor CELF4 Is Dysregulated in Neuroendocrine Tumors, Where It Can Enhance Aggressiveness Features

Introduction: There is increasing evidence that alterations in alternative splicing are linked to key tumor features in different cancers. Besides mutations, dysregulation of the splicing machinery would represent the main underlying cause for these alterations. Indeed, splicing dysregulation is emerging as a novel, transversal cancer hallmark, due to its association with multiple dysfunctions in tumor cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Alors-Pérez E

Authors: Alors-Pérez E, Pedraza-Arévalo S, Vázquez-Borrego M, Blázquez-Encinas R, Herrera-Martínez A,

Keywords: PanNET, CELF4, splicing, aggressiveness, pituitary tumors,

#2964 Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing

Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: La Salvia A

Authors: La Salvia A, Espinosa Olarte P, Modrego Sanchez A, Riesco Martinez M, Garcia Carbonero R,

Keywords: Esophageal neuroendocrine carcinoma, tumor genome sequencing, immunotherapy, tumor burden, personalized therapy,

#2801 IMMUNeOCT: OCT LAR in the Induction of Immunologic Response in Patients with Neuroendocrine Neoplasms (NENs): A Perspective Observational and Translational Study (EudraCT2017-001613-83)

Introduction: The possible impact of octreotide (OCT) Long-Acting Release (LAR) on the immune system regulation is largely unexplored.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ottaiano A, Rea G, Capozzi M, Napolitano M, Tatangelo F,

Keywords: Octreotide, Tregs, MDSCs, immune system,

#2269 Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?

Introduction: Altered expression of Insulin-like Growth Factor-1 (IGF-1), its receptor (IGF-1R), Connective Tissue Growth Factor (CTGF) and Hypoxia Factor-1 (HIF-1), has been implicated in tumorigenesis. These factors have not been studied systematically in Pulmonary Carcinoids (PCs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Tsolakis A, Kanakis G, Grimelius G, Papaioannou D, Kaltsas G,

Keywords: IGF-1, IGF-1R, CTGF, HIF-1, Ki-67,

#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?

Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Furnace M

Authors: Furnace M, Muller G, Rundell C, Shah R, Luong T,

Keywords: G3, well-differentiated, poorly differentiated, Ki-67,